Preview

Кардиология

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Доступ платный или только для Подписчиков

Как сохранить приверженность к приему антикоагулянта у пациента с фибрилляцией предсердий?

https://doi.org/10.18087/cardio.2019.11.n724

Полный текст:

Аннотация

Менее обременительное, по сравнению с варфарином, лечение прямыми пероральными антикоагулянтами (ППОАК) способно привести к лучшей приверженности к терапии больных с фибрилляцией предсердий (ФП). Однако у определенного числа пациентов с ФП, которым рекомендовались ППОАК, рецидивирует кардиоэмболический инсульт, что в значительной степени связано с невыполнением больными врачебных рекомендаций. Назначение ППОАК в качестве препаратов первой линии не гарантирует высокую приверженность больных с неклапанной ФП. Для пациентов с ФП пожилого и старческого возраста с многочисленными сопутствующими заболеваниями предложение более простой схемы фармакотерапии особенно актуально. В ряде крупных современных исследований, выполненных в клинической практике, установлена высокая приверженность к терапии ривароксабаном, которая может быть следствием приема данного ППОАК 1 раз в сутки, его безопасности и эффективности.

Об авторе

С. Г. Канорский
ФГБОУ ВО «Кубанский государственный медицинский университет» Минздрава России
Россия
Краснодар


Список литературы

1. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC et al. 2019 AHA/ACC/HRS Focused update of the 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation. Journal of the American College of Cardiology. 2019;74 (1):104–32. DOI: 10.1016/j.jacc.2019.01.011

2. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. 2016;37 (38):2893–962. DOI: 10.1093/eurheartj/ehw210

3. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP et al. Heart Disease and Stroke Statistics – 2019 Update: A Report From the American Heart Association. Circulation. 2019;139 (10):e56–528. DOI: 10.1161/CIR.0000000000000659

4. Bunch TJ, Gersh BJ. Rhythm Control Strategies and the Role of Antiarrhythmic Drugs in the Management of Atrial Fibrillation: Focus on Clinical Outcomes. Journal of General Internal Medicine. 2011;26 (5):531–7. DOI: 10.1007/s11606­010­1574­8

5. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 2009;361 (12):1139–51. DOI: 10.1056/NEJMoa0905561

6. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine. 2011;365 (10):883–91. DOI: 10.1056/NEJMoa1009638

7. Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M et al. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 2011;365 (11):981–92. DOI: 10.1056/NEJMoa1107039

8. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL et al. Edoxaban versus warfarin in patients with atrial fibrillation. The New England Journal of Medicine. 2013;369 (22):2093–104. DOI: 10.1056/NEJMoa1310907

9. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non­vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European Heart Journal. 2018;39 (16):1330–93. DOI: 10.1093/eurheartj/ehy136

10. Shinoda N, Mori M, Tamura S, Korosue K, Kose S, Kohmura E. Risk of Recurrent Ischemic Stroke with Unintended Low­Dose Oral Anticoagulant Therapy and Optimal Timing of Review. Journal of Stroke and Cerebrovascular Diseases. 2018;27 (6):1546–51. DOI: 10.1016/j.jstrokecerebrovasdis.2018.01.002

11. Rodriguez RA, Carrier M, Wells PS. Non­adherence to new oral anticoagulants: a reason for concern during long­term anticoagulation? Journal of Thrombosis and Haemostasis. 2013;11 (2):390–4. DOI: 10.1111/jth.12086

12. McHorney CA, Crivera C, Laliberté F, Germain G, Wynant W, Lefebvre P. Adherence to rivaroxaban versus apixaban among patients with non­valvular atrial fibrillation: Analysis of overall population and subgroups of prior oral anticoagulant users. PLOS ONE. 2018;13 (4):e0194099. DOI: 10.1371/journal.pone.0194099

13. Alberts MJ, Peacock WF, Fields LE, Bunz TJ, Nguyen E, Milentijevic D et al. Association between once­ and twice­daily direct oral anticoagulant adherence in nonvalvular atrial fibrillation patients and rates of ischemic stroke. International Journal of Cardiology. 2016;215:11–3. DOI: 10.1016/j.ijcard.2016.03.212

14. Madhavan M, Yao X, Sangaralingham LR, Asirvatham SJ, Friedman PA, McLeod CJ et al. Ischemic Stroke or Systemic Embolism after Transseptal Ablation of Arrhythmias in Patients with Cardiac Implantable Electronic Devices. Journal of the American Heart Association. 2016;5 (4):e003163. DOI: 10.1161/JAHA.115.003163

15. Borne RT, O’Donnell C, Turakhia MP, Varosy PD, Jackevicius CA, Marzec LN et al. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration. BMC Cardiovascular Disorders. 2017;17 (1):236. DOI: 10.1186/s12872­017­0671­6

16. Deshpande CG, Kogut S, Laforge R, Willey C. Impact of medication adherence on risk of ischemic stroke, major bleeding and deep vein thrombosis in atrial fibrillation patients using novel oral anticoagulants. Current Medical Research and Opinion. 2018;34 (7):1285–92. DOI: 10.1080/03007995.2018.1428543

17. Gellad WF, Thorpe CT, Steiner JF, Voils CI. The myths of medication adherence. Pharmacoepidemiology and Drug Safety. 2017;26 (12):1437–41. DOI: 10.1002/pds.4334

18. Spivey CA, Liu X, Qiao Y, Mardekian J, Parker RB, Phatak H et al. Stroke associated with discontinuation of warfarin therapy for atrial fibrillation. Current Medical Research and Opinion. 2015;31 (11):2021–9. DOI: 10.1185/03007995.2015.1082995

19. Hurtado­Navarro I, García­Sempere A, Rodríguez­Bernal C, SantaAna­Tellez Y, Peiró S, Sanfélix­Gimeno G. Estimating Adherence Based on Prescription or Dispensation Information: Impact on Thresholds and Outcomes. A Real­World Study With Atrial Fibrillation Patients Treated With Oral Anticoagulants in Spain. Frontiers in Pharmacology. 2018;9:1353. DOI: 10.3389/fphar.2018.01353

20. Maura G, Pariente A, Alla F, Billionnet C. Adherence with direct oral anticoagulants in nonvalvular atrial fibrillation new users and associated factors: a French nationwide cohort study. Pharmacoepidemiology and Drug Safety. 2017;26 (11):1367–77. DOI: 10.1002/pds.4268

21. Tsai K, Erickson SC, Yang J, Harada AS, Solow BK, Lew HC. Adherence, persistence, and switching patterns of dabigatran etexilate. The American Journal of Managed Care. 2013;19 (9):e325–332. PMID: 24449962

22. Shore S, Carey EP, Turakhia MP, Jackevicius CA, Cunningham F, Pilote L et al. Adherence to dabigatran therapy and longitudinal patient outcomes: Insights from the Veterans Health Administration. American Heart Journal. 2014;167 (6):810–7. DOI: 10.1016/j.ahj.2014.03.023

23. Beyer­Westendorf J, Ehlken B, Evers T. Real­world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation. Europace. 2016;18 (8):1150–7. DOI: 10.1093/europace/euv421

24. Shore S, Ho PM, Lambert­Kerzner A, Glorioso TJ, Carey EP, Cunningham F et al. Site­Level Variation in and Practices Associated with Dabigatran Adherence. JAMA. 2015;313 (14):1443–50. DOI: 10.1001/jama.2015.2761

25. Thorne K, Jayathissa S, Dee S, Briggs N, Taylor J, Reid S et al. Adherence and outcomes of patients prescribed dabigatran (Pradaxa) in routine clinical practice: Adherence and outcomes of patients. Internal Medicine Journal. 2014;44 (3):261–5. DOI: 10.1111/imj.12370

26. Yamada K, Nabeshima T. Pharmacist­managed clinics for patient education and counseling in Japan: current status and future perspectives. Journal of Pharmaceutical Health Care and Sciences. 2015;1 (1):2. DOI: 10.1186/s40780­014­0001­4

27. Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T et al. A new taxonomy for describing and defining adherence to medications: New taxonomy for adherence to medications. British Journal of Clinical Pharmacology. 2012;73 (5):691–705. DOI: 10.1111/j.1365–2125.2012.04167.x

28. Finkelman BS, French B, Bershaw L, Kimmel SE. Factors affecting time to maintenance dose in patients initiating warfarin. Pharmacoepidemiology and Drug Safety. 2015;24 (3):228–36. DOI: 10.1002/pds.3735

29. Ho PM, Magid DJ, Shetterly SM, Olson KL, Maddox TM, Peterson PN et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. American Heart Journal. 2008;155 (4):772–9. DOI: 10.1016/j.ahj.2007.12.011

30. Mochari H, Ferris A, Adigopula S, Henry G, Mosca L. Cardiovascular disease knowledge, medication adherence, and barriers to preventive action in a minority population. Preventive Cardiology. 2007;10 (4):190–5. PMID: 17917515

31. Song X, Sander SD, Varker H, Amin A. Patterns and Predictors of Use of Warfarin and Other Common Long­Term Medications in Patients with Atrial Fibrillation: American Journal Cardiovascular Drugs. 2012;12 (4):245–53. DOI: 10.2165/11632540­000000000­00000

32. Osterberg L, Blaschke T. Adherence to medication. The New England Journal of Medicine. 2005;353 (5):487–97. DOI: 10.1056/NEJMra050100

33. Johnson ME, Lefèvre C, Collings S­L, Evans D, Kloss S, Ridha E et al. Early real­world evidence of persistence on oral anticoagulants for stroke prevention in non­valvular atrial fibrillation: a cohort study in UK primary care. BMJ Open. 2016;6 (9):e011471. DOI: 10.1136/bmjopen­2016–011471

34. Collings S­L, Lefèvre C, Johnson ME, Evans D, Hack G, Stynes G et al. Oral anticoagulant persistence in patients with non­valvular atrial fibrillation: A cohort study using primary care data in Germany. PLOS ONE. 2017;12 (10):e0185642. DOI: 10.1371/journal.pone.0185642

35. Sørensen R, Jamie Nielsen B, Langtved Pallisgaard J, Ji­Young Lee C, Torp­Pedersen C. Adherence with oral anticoagulation in non­valvular atrial fibrillation: a comparison of vitamin K antagonists and non­vitamin K antagonists. European Heart Journal – Cardiovascular Pharmacotherapy. 2017;3 (3):151–6. DOI: 10.1093/ehjcvp/pvw048

36. Lip GYH, Pan X, Kamble S, Kawabata H, Mardekian J, Masseria C et al. Discontinuation risk comparison among ‘real­world’ newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban. PLOS ONE. 2018;13 (4):e0195950. DOI: 10.1371/journal.pone.0195950

37. Raparelli V, Proietti M, Cangemi R, Lip GYH, Lane DA, Basili S. Adherence to oral anticoagulant therapy in patients with atrial fibrillation: Focus on non­vitamin K antagonist oral anticoagu lants. Thrombosis and Haemostasis. 2017;117 (02):209–18. DOI: 10.1160/TH16­10­0757

38. Miyasaka Y. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114 (2):119–25. DOI: 10.1161/CIRCULATIONAHA.105.595140

39. Andrade JG, Krahn AD, Skanes AC, Purdham D, Ciaccia A, Connors S. Values and Preferences of Physicians and Patients with Nonvalvular Atrial Fibrillation Who Receive Oral Anticoagulation Therapy for Stroke Prevention. Canadian Journal of Cardiology. 2016;32 (6):747–53. DOI: 10.1016/j.cjca.2015.09.023

40. Rosanio S, Keylani AM, D’Agostino DC, DeLaughter CM, Vitarelli A. Pharmacology, benefits, unaddressed questions, and pragmatic issues of the newer oral anticoagulants for stroke prophylaxis in non­valvular atrial fibrillation and proposal of a management algorithm. International Journal of Cardiology. 2014;174 (3):471–83. DOI: 10.1016/j.ijcard.2014.04.179

41. Rivard L, Khairy P. Mechanisms, Clinical Significance, and Prevention of Cognitive Impairment in Patients With Atrial Fibrillation. Canadian Journal of Cardiology. 2017;33 (12):1556–64. DOI: 10.1016/j.cjca.2017.09.024

42. Diener H­C, Hart RG, Koudstaal PJ, Lane DA, Lip GYH. Atrial Fibrillation and Cognitive Function. Journal of the American College of Cardiology. 2019;73 (5):612–9. DOI: 10.1016/j.jacc.2018.10.077

43. Rydén L, Zettergren A, Seidu NM, Guo X, Kern S, Blennow K et al. Atrial fibrillation increases the risk of dementia amongst older adults even in the absence of stroke. Journal of Internal Medicine. 2019;286 (1):101–10. DOI: 10.1111/joim.12902

44. Conen D, Rodondi N, Müller A, Beer JH, Ammann P, Moschovitis G et al. Relationships of Overt and Silent Brain Lesions With Cognitive Function in Patients With Atrial Fibrillation. Journal of the American College of Cardiology. 2019;73 (9):989–99. DOI: 10.1016/j.jacc.2018.12.039

45. Desai NR, Krumme AA, Schneeweiss S, Shrank WH, Brill G, Pezalla EJ et al. Patterns of Initiation of Oral Anticoagulants in Patients with Atrial Fibrillation— Quality and Cost Implications. The American Journal of Medicine. 2014;127 (11):1075–1082.e1. DOI: 10.1016/j.amjmed.2014.05.013

46. Forslund T, Wettermark B, Hjemdahl P. Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation. European Journal of Clinical Pharmacology. 2016;72 (3):329–38. DOI: 10.1007/s00228­015­1983­z

47. Yao X, Abraham NS, Alexander GC, Crown W, Montori VM, Sangaralingham LR et al. Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation. Journal of the American Heart Association. 2016;5 (2):e003074. DOI: 10.1161/JAHA.115.003074

48. Kim H, Lee YS, Kim T­H, Cha M­J, Lee JM, Park J et al. A prospective survey of the persistence of warfarin or NOAC in nonvalvular atrial fibrillation: a COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE­AF). The Korean Journal of Internal Medicine. 2019; [Epub ahead of print]. DOI: 10.3904/kjim.2017.415

49. Vrijens B, Heidbuchel H. Non­vitamin K antagonist oral anticoagulants: considerations on once­ vs. twice­daily regimens and their potential impact on medication adherence. Europace. 2015;17 (4):514–23. DOI: 10.1093/europace/euu311

50. Kreutz R, Persson PB, Kubitza D, Thelen K, Heitmeier S, Schwers S et al. Dissociation between the pharmacokinetics and pharmacodynamics of once­daily rivaroxaban and twice­daily apixaban: a randomized crossover study. Journal of Thrombosis and Haemostasis. 2017;15 (10):2017–28. DOI: 10.1111/jth.13801

51. Brown JD, Shewale AR, Talbert JC. Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention for Newly Diagnosed and Treatment­Naive Atrial Fibrillation Patients: An Update Using 2013–2014 Data. Journal of Managed Care & Specialty Pharmacy. 2017;23 (9):958–67. DOI: 10.18553/jmcp.2017.23.9.958

52. Crivera C, Nelson WW, Bookhart B, Martin S, Germain G, Laliberté F et al. Pharmacy quality alliance measure: adherence to non­warfarin oral anticoagulant medications. Current Medical Research and Opinion. 2015;31 (10):1889–95. DOI: 10.1185/03007995.2015.1077213

53. McHorney CA, Ashton V, Laliberté F, Germain G, Wynant W, Crivera C et al. Adherence to Rivaroxaban Compared with Other Oral Anticoagulant Agents Among Patients with Nonvalvular Atrial Fibrillation. Journal of Managed Care & Specialty Pharmacy. 2017;23 (9):980–8. DOI: 10.18553/jmcp.2017.23.9.980

54. Emren SV, Zoghi M, Berılgen R, Özdemir İH, Çelik O, Çetin N et al. Safety of once­ or twice­daily dosing of non­vitamin K antagonist oral anticoagulants (NOACs) in patients with nonvalvular atrial fibrillation: A NOAC­TR study. Bosnian Journal of Basic Medical Sciences. 2018;18 (2):185–90. DOI: 10.17305/bjbms.2017.2279

55. Deshpande CG, Kogut S, Willey C. Real­World Health Care Costs Based on Medication Adherence and Risk of Stroke and Bleeding in Patients Treated with Novel Anticoagulant Therapy. Journal of Managed Care & Specialty Pharmacy. 2018;24 (5):430–9. DOI: 10.18553/jmcp.2018.24.5.430

56. Brown JD, Shewale AR, Talbert JC. Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment­Naïve Nonvalvular Atrial Fibrillation. Journal of Managed Care & Specialty Pharmacy. 2016;22 (11):1319–29. DOI: 10.18553/jmcp.2016.22.11.1319

57. McHorney CA, Peterson ED, Ashton V, Laliberté F, Crivera C, Germain G et al. Modeling the impact of real­world adherence to oncedaily (QD) versus twice­daily (BID) non­vitamin K antagonist oral anticoagulants on stroke and major bleeding events among non­valvular atrial fibrillation patients. Current Medical Research and Opinion. 2019;35 (4):653–60. DOI: 10.1080/03007995.2018.1530205

58. Weeda ER, Coleman CI, McHorney CA, Crivera C, Schein JR, Sobieraj DM. Impact of once­ or twice­daily dosing frequency on adherence to chronic cardiovascular disease medications: A meta­regression analysis. International Journal of Cardiology. 2016;216:104–9. DOI: 10.1016/j.ijcard.2016.04.082

59. Martinez BK, Baker WL, Sood NA, Bunz TJ, Meinecke A­K, Eriksson D et al. Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2019;39 (2):196–203. DOI: 10.1002/phar.2213

60. Coleman CI, Peacock WF, Bunz TJ, Alberts MJ. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack. Stroke. 2017;48 (8):2142–9. DOI: 10.1161/STROKEAHA.117.017474

61. Staerk L, Gerds TA, Lip GYH, Ozenne B, Bonde AN, Lamberts M et al. Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study. Journal of Internal Medicine. 2018;283 (1):45–55. DOI: 10.1111/joim.12683

62. Jacobs MS, Schouten JF, de Boer PT, Hoffmann M, Levin L­Å, Postma MJ. Secondary adherence to non­vitamin­K antagonist oral anticoagulants in patients with atrial fibrillation in Sweden and the Netherlands. Current Medical Research and Opinion. 2018;34 (10):1839–47. DOI: 10.1080/03007995.2018.1459528

63. Rossi AP, Facchinetti R, Ferrari E, Nori N, Sant S, Masciocchi E et al. Predictors of self­reported adherence to direct oral anticoagulation in a population of elderly men and women with non­valvular atrial fibrillation. Journal of Thrombosis and Thrombolysis. 2018;46 (2):139–44. DOI: 10.1007/s11239­018­1679­1

64. Hecker J, Marten S, Keller L, Helmert S, Michalski F, Werth S et al. Effectiveness and safety of rivaroxaban therapy in daily­care patients with atrial fibrillation: Results from the Dresden NOAC Registry. Thrombosis and Haemostasis. 2016;115 (05):939–49. DOI: 10.1160/TH15­10­0840

65. Kirchhof P, Radaideh G, Kim Y­H, Lanas F, Haas S, Amarenco P et al. Global Prospective Safety Analysis of Rivaroxaban. Journal of the American College of Cardiology. 2018;72 (2):141–53. DOI: 10.1016/j.jacc.2018.04.058


Для цитирования:


Канорский С.Г. Как сохранить приверженность к приему антикоагулянта у пациента с фибрилляцией предсердий? Кардиология. 2019;59(11):76-83. https://doi.org/10.18087/cardio.2019.11.n724

For citation:


Kanorskii S.G. How to maintain an adherence to oral anticoagulant in a patient with atrial fibrillation? Kardiologiia. 2019;59(11):76-83. (In Russ.) https://doi.org/10.18087/cardio.2019.11.n724

Просмотров: 285


ISSN 0022-9040 (Print)
ISSN 2412-5660 (Online)